Abstract | OBJECTIVES: DESIGN: We conducted a cost-utility analysis with a cohort state transition decision model using a lifetime time horizon, 1.5% discount rate, and outcomes reported as cost per quality-adjusted life year. Literature reviews were conducted to inform the model variables. Deterministic and probabilistic sensitivity analyses were conducted to assess uncertainty in the model. SETTING: Canadian publicly funded healthcare system. PATIENTS: INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: In our model, the use of venovenous extracorporeal membrane oxygenation compared with lung protective ventilation resulted in a gain of 5.2 life years and 4.05 quality-adjusted life years, at an additional lifetime cost of $145,697 Canadian dollars. The incremental cost-effectiveness ratio was $36,001/quality-adjusted life year. Sensitivity analyses show that the incremental cost-effectiveness ratio is sensitive to the efficacy of extracorporeal membrane oxygenation therapy and costs. CONCLUSIONS:
|
Authors | Kali A Barrett, Neil Hawkins, Eddy Fan |
Journal | Critical care medicine
(Crit Care Med)
Vol. 47
Issue 2
Pg. 186-193
(02 2019)
ISSN: 1530-0293 [Electronic] United States |
PMID | 30312186
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adult
- Canada
- Cost-Benefit Analysis
- Extracorporeal Membrane Oxygenation
(economics, methods)
- Health Care Costs
- Humans
- Models, Economic
- Quality-Adjusted Life Years
- Respiratory Distress Syndrome
(economics, therapy)
|